Tharimmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing therapeutic candidates for inflammatory and immunologic conditions with unmet need. It has a transmucosal film product, TH104, is a Phase II ready clinical candidate and an oral biologic as well as two bispecific biologics in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active compound nalmefene onto a thin film which adheres inside of the mouth on the cheek and biodegrades. TH104 is an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. It is also developing an early-stage pipeline of novel therapeutic candidates targeting validated high value immune-oncology targets including human epidermal growth factor receptor 2, human EGF receptor 3 and programmed cell death protein. The Company is developing antibodies, including bispecific antibodies, antibody drug conjugates, among others.
Mã chứng khoán- -
Tên công ty- -
Ngày IPO- -
Giám đốc điều hành- -
Số lượng nhân viên- -
Loại chứng khoán- -
Kết thúc năm tài chính- -
Địa chỉ- -
Thành phố- -
Sàn giao dịch chứng khoán- -
Quốc gia- -
Mã bưu điện- -
Điện thoại- -
Trang web- -
Mã chứng khoán- -
Ngày IPO- -
Giám đốc điều hành- -